Therapies

Neogene Therapeutics Grabs $110M to Tackle Solid Tumors With Cell Therapy

7 days ago   |   By Xconomy

Cell therapy offers another option for addressing the most difficult blood cancer cases, but such treatments, which are engineered from a patient's own immune cells, don't yet work on solid tumors. Neogene Therapeutics is developing technology with the potential to bring cell therapies to solid tumors and it now has $110 million to advance its research toward human testing. The experimental therapies of Amsterdam-based Neogene target neoantigens, which are, as the term suggests, new antigens. These proteins arise from the mutations that drive cancer and they're abundant on the surface of...
Read more ...

 


Search by Tags

   Therapies      Engineering      Immunity      Cancer      Therapeutics      Protein      Research      Boston blog main      Boston top stories      Europe      Europe blog main      Europe top stories      National blog main      National top stories      New York blog main      New York top stories      San Francisco blog main      San Francisco top stories      Allogene Therapeutics      Arie Belldegrun      BioNtech      Biotech      Cancer Drugs      Carsten Linnemann      Cell Therapy      Clinical trials      David Chang      Deals      EcoR1 Capital      Eureka Therapeutics      FDA      Gritstone Oncology      Investing      Jeito Capital      Life Sciences      Neogene Therapeutics      Neon Therapeutics      Polaris Partners      Pontifax      Startups      Syncona      T-Cell FActory      TCR2 therapeutics      TPG Capital      Two River Group      Vida Ventures  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Berkeley Team Plays Key Role in Analysis of Particle Interactions That...

Berkeley Team Plays Key Role in Analysis of Particle Interactions That Produce Matter From Light

This image shows a reconstruction of a particle event at CERN's ATLAS detector that produced W bosons from photons, which are particles of light. Researchers at the U.S... Read more ...

Tau-Targeting Alzheimer's Drug from AC Immune, Roche Fails in Phase 2

Tau-Targeting Alzheimer's Drug from AC Immune, Roche Fails in Phase 2

An Alzheimer's disease drug from partners AC Immune and Roche has failed a mid-stage clinical trial, adding another compound to the list of experimental therapies that have... Read more ...

Athira CEO Kawas: Alzheimer's Drug Aims for “Recovery of Brain Function”

Athira CEO Kawas: Alzheimer's Drug Aims for “Recovery of Brain Function”

The key to Athira Pharma's approach to Alzheimer's disease is already inside each of us: a repair mechanism that can regenerate damaged neurons. What's needed to begin the... Read more ...

Gene Therapy Firms Seek Clarity on FDA Exclusivity, Orphan Designations

Gene Therapy Firms Seek Clarity on FDA Exclusivity, Orphan Designations

Gene therapy product developers are seeking more clarity from the US Food and Drug Administration on when viral vectors from the same class will be considered sufficiently... Read more ...

Checkmate, Chromosome 8: The First End-to-End Sequence of a Human Autosome

Checkmate, Chromosome 8: The First End-to-End Sequence of a Human Autosome

Even in the field of genomics where new breakthroughs occur every few months, completion of the first-ever fully sequenced human autosome is a momentous achievement. Highly... Read more ...

Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal

Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal

Grail is set to be acquired for $8 billion by Illumina, the gene sequencing giant that formed the cancer diagnostics developer and spun it out as a separate company four years... Read more ...

Xconomy Awards On-Demand ‘Meet the Finalists' Webcast Series Continues This Week

Xconomy Awards On-Demand ‘Meet the Finalists' Webcast Series Continues This Week

The 2020 National Xconomy Awards complimentary two-week, 11-part, on-demand Meet the Finalists daily webcast series continues this Tuesday and Wednesday at 11 a.m. ET... Read more ...

Knockoff Boosted Tree for Model-Free Variable Selection

AbstractMotivationThe recently proposed knockoff filter is a general framework for controlling the false discovery rate when performing variable selection. This powerful new... Read more ...

IsoResolve: Predicting Splice Isoform Functions by Integrating Gene and...

AbstractMotivationHigh resolution annotation of gene functions is a central goal in functional genomics. A single gene may produce multiple isoforms with different functions... Read more ...

Bedtk: Finding Interval Overlap with Implicit Interval Tree

AbstractSummaryWe present bedtk, a new toolkit for manipulating genomic intervals in the BED format. It supports sorting, merging, intersection, subtraction and the calculation... Read more ...